Lupin, Inc.

Nandu Baban Bhise

Girij Pal Singh

Sachin Arun Sasane

Krishnat Hanmant Kumbhar

Rajesh Harishankar Vyas

Vijay Ahire

Amol Deshmukh

Akshat Bhatnagar

Devendra Verma

Gurvinder Pal Singh

Radhakrishna Bhikaji Shivdavkar

Rajinder Singh Siyan

Hemraj Mahadeorao Lande

Pankaj Ramchandra Chaudhari

Ananda Pundlik Sapdhare

Sukhdeo Sampat Gunjal

Raju Muktaji Walunj

Devendrakumar Paramsukh Varma

Arunkumar Digambar Patil

Anurag Trivedi

Puma Chandra Ray

Mithun Dasharath Surwase

Shantanu Gokuldas Varade

Palash Sanphui

Govind Dnyanoba Ausekar

The present invention provides an improved process for the preparation of Efinaconazole in higher yield by the ring-opening addition reaction of epoxytriazole with 4-methylenepiperidine or its acid addition salt under mild conditions without using a large excess of 4-methylenepiperidine in the presence of an alkali or an alkaline earth metal halide.

Process for the preparation of Efinaconazole

The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.

Process for preparation of apremilast and novel polymorphs thereof

The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74&#xb1;0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5&#xb1;0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.

Process for preparation of cysteamine bitartrate

The present invention provides a novel process for preparation of darunavir that involves reduction of [(1S,2R)-3-[[(4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester, of formula (5). The present invention also provides darunavir ethanolate of particle size wherein dis less than 130 &#x3bc;m, dis less than 30 &#x3bc;m, dis less than 10 &#x3bc;m and process for its preparation.

Process for preparation of darunavir and darunavir ethanolate of fine particle size

Growing community of inventors

Maharashtra, India

Nandu Baban Bhise